GlassScriptPhysician profile
Samantha Jackson
NPI 1801191754
$2,483.87
in general payments reported to CMS, 2019-2025
30 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $575 · 2023: $607 · 2024: $518 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $480.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.74 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $199.24 | 2021-2024 | |
| Amgen INC. | $151.91 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $137.11 | 2022-2024 | Wegovy |
| Abbvie INC. | $136.13 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $115.50 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.02 | 2021-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $79.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $76.32 | 2021 | |
| Pfizer INC. | $71.56 | 2023-2025 | |
| Dexcom, INC. | $62.37 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $61.06 | 2021-2024 | Airsupra |
| Sumitomo Pharma America, INC. | $60.37 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $58.39 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.30 | 2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $50.68 | 2021-2023 | |
| Abbott Laboratories | $44.93 | 2023 | Freestyle Libre 2 |
| Medtronic, INC. | $34.49 | 2022-2024 | Intellis Adaptivestim |
| Otsuka America Pharmaceutical, INC. | $34.46 | 2023-2024 | Nuedexta, Rexulti |
| Phathom Pharmaceuticals, INC. | $34.00 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $33.06 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.52 | 2022 | |
| Amarin Pharma, INC. | $14.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.11 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.05 | 2022 | |
| Dynavax Technologies Corporation | $13.72 | 2021 | |
| Astellas Pharma US INC | $13.03 | 2023 | Myrbetriq |
| Eisai INC. | $12.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.